bitBiome

Tokyo, Japan· Est. 2020

bitBiome uses single-cell genomics to decode unculturable microbes, building a proprietary database for enzyme discovery and biomanufacturing solutions.

bitbiome.co.jp

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

Private Company

Funding information not available

AI Company Overview

bitBiome uses single-cell genomics to decode unculturable microbes, building a proprietary database for enzyme discovery and biomanufacturing solutions.

Technology Platform

bit-MAP®: A single-cell genomics platform that sequences complete genomes from individual, unculturable microbial cells without prior isolation or cultivation, providing strain-level resolution.

Opportunities

Growth opportunities include expanding its proprietary genomic database (bit-GEM) for novel enzyme discovery, securing more strategic partnerships in industrial biotech, agriculture, and nutrition, and developing applications for decarbonization and circular economy goals.

Risk Factors

Key risks include competition from other metagenomic and synthetic biology platforms, the technical and commercial challenge of scaling its single-cell process, and the uncertainty in translating genomic data into high-performance, market-ready biocatalysts.

Competitive Landscape

Competes with metagenomic screening companies and enzyme engineering platforms like Ginkgo Bioworks. Differentiation lies in its single-cell genomics foundation, which provides high-resolution, complete genomes from unculturable microbes, and its integrated platform from sequencing to enzyme discovery.

More companies in Japan →